Attovia Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 15.19 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 693.44M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company’s products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn’s disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.
Details
| Name | Attovia Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 44 |
| Founded | 2023 |
| Ipo Date | 2026-08-05 |
| Ceo | Tao Fu |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 17.00 |
| Isin | US04987L1026 |
| Cusip | 04987L102 |
| Cik | 2058707 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Tao Fu M.B.A., M.S. | Chief Executive Officer, President and Director |
| Dr. Petter Veiby Ph.D. | Chief Scientific Officer |
| Dr. Hubert C. Chen M.D., M.P.H. | Chief Medical Officer |
| Steven Chan CPA | Chief Financial Officer |
| Dr. Hangjun Zhan Ph.D. | Chief Technology Officer |
| Dr. Bora Han Ph.D. | Vice President and Head of Preclinical Development |
| Dr. Zaneta Odrowaz Ph.D. | Chief Business Officer, Treasurer and Secretary |
Contact
| Address | 1091 Industrial Road, Suite 310, San Carlos, California 94070, United States |
| Phone | 510 399 5001 |
| Website | https://www.attovia.com |